Daiichi Sankyo, Yakult, And Generics Get Approval For Irinotecan Additional Indication Of Pediatric Malignancy
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo, Yakult, Sawai, and Hospira Japan received approval for an irinotecan additional indication for pediatric malignant solid tumors.